CHAPTER 5

HAEMODIALYSIS

Leonie Excell
Mark Marshall
and
Stephen McDonald



STOCK AND FLOW

AUSTRALIA

The annual stock and flow of haemodialysis patients during the period 1999-2003 is shown in Figures 5.1 and 5.2.

There were 5,851 patients (294 per million) receiving treatment at 31st December 2003, an increase of 7%; 38% were hospital based (37% in 2002), 51% were in satellite centres (limited or self-care) (49% in 2002) and 13% at home (14% in 2002). The proportion of patients receiving satellite haemodialysis increased by 11% (10% in 2002).

The proportion of all dialysis patients who were using home haemodialysis in each State was 19% for New South Wales, 12% for the ACT and less than 8% for the other States (fig 4.1).

A total of 1,667 patients received haemodialysis for the first time during the year, a 6% increase from last year; after a 2% decrease in 2002. The modal age group was 65-74 years (24%).

Of the 5,851 patients dialysing, 44% were 65 years or older and 8% less than 35 years old. There was an increase in the number of new patients commencing haemodialysis, 26% in the 15-24 year group, 7% in the 25-34 year group, 15% in the 35-44 year group and 29% in the 75-84 year group (fig 5.3).

Figure 5.1

Stock and Flow of Haemodialysis Patients 1999 - 2003

	1999	2000	2001	2002	2003
Australia					
Patients new to HD	1526	1519	1607	1572	1667
First Dialysis Treatment	1303	1286	1380	1345	1411
Previous Dialysis (PD)	188	207	198	200	226
Failed Transplant	35	26	29	27	30
Transplanted	329	362	383	393	372
Deaths	644	684	771	713	832
Never Transplanted	575	619	707	652	757
Previous Transplant	69	65	64	61	75
Permanent Transfers Out (>12 months)	221	254	269	235	312
Temporary Transfers (<12 months)	153	156	128	116	76
Patients Dialysing at 31 December	4343	4674	5043	5480	5851
Patients Dialysing at Home 31 December	706	742	773	777	772
% of all Home Dialysis Patients	30%	30%	30%	31%	30%
New Zealand					
Patients new to HD	259	356	336	336	352
First Dialysis Treatment	189	264	277	288	286
Previous Dialysis (PD)	62	81	53	41	61
Failed Transplant	8	11	6	7	5
Transplanted	62	50	60	61	64
Deaths	93	106	127	109	132
Never Transplanted	85	95	114	99	115
Previous Transplant	8	11	13	10	17
Permanent Transfers Out (>12 months)	79	116	91	119	122
Temporary Transfers (<12 months)	32	37	18	30	15
Patients Dialysing at 31 December	562	655	754	827	930
Patients Dialysing at Home 31 December	179	188	200	228	234
% of all Home Dialysis Patients	21%	22%	22%	23%	23%

The proportion of all dialysis patients in each age group who were using haemodialysis is shown in Figure 5.6.

For more detail regarding age and mode of haemodialysis in each State see Appendix II at the Website (www.anzdata.org.au/ANZDATA/AnzdataReport/download.htm).

There were 372 transplant operations, a 5% decrease from 2002; representing 6% of all patients dialysing and 10% of those patients <65 years. Thirty two patients aged >=65 years were transplanted.

There were 832 deaths, representing 14.7 deaths per 100 patient years (11.2% of patients at risk) (fig 3.8).

For more detail of cause of death see Appendix II at the Website (www.anzdata.org.au/ANZDATA/AnzdataReport/download.htm).

New Zealand

The annual stock and flow of haemodialysis patients during the period 1999-2003 is shown in Figure 5.4 and 5.5.

There were 930 patients (232 per million) receiving treatment at 31st December 2003, a 12% increase compared to 2002. Hospital based haemodialysis increased from last year to 46% (45% in 2002), satellite haemodialysis remained the same at 28% and home haemodialysis decreased from 28% in 2002 to 25% this year.

There was a 5% increase in the number of new haemodialysis patients in the survey period. In 2001 and 2002 the number had remained the same.

Modal age group for new patients was 65-74 years (26%); 36% were ≥ 65 years and 10% < 35 years (fig 5.5).

Figure 5.2






Figure 5.3									Au	strali
St	ock an	d Flow		aemodi umber (-	s 199	99 - 2	2003		
Age Groups	1	.999	2	000	2	001	2	:002	2	003
New Patients *										
00-14 years	10	(<1%)	5	(<1%)	13	(<1%)	11	(<1%)	9	(<1%)
15-24 years	47	(3%)	56	(4%)	43	(3%)		(3%)	48	(3%)
25-34 years	102	(7%)	107	(7%)	106	(7%)	85	(5%)	91	(5%)
35-44 years	173	(11%)		(10%)	178	(11%)	136	(9%)	156	(9%)
45-54 years	268	(17%)	254	(17%)	274	(17%)		(17%)	277	(17%)
55-64 years	306	(20%)	295	(19%)	318	(20%)	320	(20%)	315	(19%)
65-74 years	419	(28%)	406	(27%)	416	(26%)	421	(27%)	407	(24%)
75-84 years	193	(13%)	237	(16%)	249	(15%)	270	(17%)	347	(21%)
>=85 years	8	(<1%)	8	(<1%)	10	(<1%)	20	(1%)	17	(1%)
Total	1526	(100%)	1519	(100%)	1607	(100%)	1572	(100%)	1667	(100%
Patients Dialysing										
00-14 years	10	(<1%)	7	(<1%)	13	(<1%)	11	(<1%)	3	(<1%)
15-24 years	98	(2%)	93	(2%)	94	(2%)	102	(2%)	101	(2%)
25-34 years	346	(8%)	354	(8%)	356	(7%)	348	(6%)	340	(6%)
35-44 years	562	(13%)	595	(13%)	605	(12%)	568	(10%)	603	(10%)
45-54 years	784	(18%)	815	(17%)	893	(18%)	949	(17%)	999	(17%)
55-64 years	895	(21%)	949	(20%)	1018	(20%)	1160	(21%)	1220	(21%)
65-74 years	1106	(26%)	1186	(25%)	1298	(26%)	1401	(26%)	1455	(25%)
75-84 years	523	(12%)	646	(14%)	737	(15%)	883	(16%)	1057	(18%)
>=85 years	19	(<1%)	29	(<1%)	29	(<1%)	58	(1%)	73	(1%)
Total	4343	(100%)	4674	(100%)	5043	(100%)	5480	(100%)	5851	(100%
Primary Renal Disease	*									
Glomerulonephritis	475	(32%)	483	(32%)	458	(28%)	420	(27%)	446	(27%)
Analgesic Nephropathy	82	(5%)	63	(4%)	86	(5%)	64	(4%)	67	(4%)
Hypertension	167	(11%)	199	(13%)	217	(13%)	244	(16%)	263	(16%)
Polycystic Disease	106	(7%)	99	(6%)	100	(6%)	87	(6%)	81	(5%)
Reflux Nephropathy	68	(4%)	69	(5%)	60	(4%)	57	(3%)	61	(3%)
Diabetic Nephropathy	357	(23%)	330	(22%)	383	(24%)	427	(27%)	432	(26%)
Miscellaneous	158	(10%)	179	(12%)	179	(11%)	181	(11%)	202	(12%)
Uncertain	113	(8%)	97	(6%)	124	(8%)	92	(6%)	115	(7%)
Total	1526	(100%)	1519	(100%)	1607	(100%)	1572	(100%)	1667	(100%

Figure 5.4

Stock and Flow of Haemodialysis Patients New Zealand 1999 - 2003




Figure 5.5								Ne	ew Zo	ealand
Sto	ock aı	nd Flow		aemod umber (is 199	99 - 2	003		
Age Groups	1	.999	2	000	2	2001	2	002	2	003
New Patients *										
00-14 years	2	(<1%)	2	(<1%)	5	(1%)	1	(<1%)	0	(0%)
15-24 years	8	(3%)	21	(6%)	9	(3%)	13	(4%)	20	(5%)
25-34 years	22	(8%)	29	(8%)	19	(6%)	19	(6%)	14	(4%)
35-44 years	25	(10%)	36	(10%)	43	(13%)	32	(10%)	35	(10%)
45-54 years	58	(22%)	78	(22%)	78	(23%)	75	(22%)	67	(19%)
55-64 years	75	(29%)	107	(30%)	84	(25%)	113	(34%)	88	(25%)
65-74 years	42	(16%)	57	(16%)	75	(22%)	65	(19%)	90	(26%)
75-84 years	26	(10%)	26	(7%)	22	(7%)	16	(5%)	38	(11%)
>=85 years	1	(<1%)	0	(0%)	1	(<1%)	2	(<1%)	0	(0%)
Total	259	(100%)	356	(100%)	336	(100%)	336	(100%)	352	(100%)
Patients Dialysing										
00-14 years	4	(<1%)	2	(<1%)	3	(<1%)	2	(<1%)	0	(0%)
15-24 years	22	(4%)	36	(6%)	30	(4%)	29	(3%)	32	(3%)
25-34 years	52	(9%)	64	(9%)	59	(8%)	64	(8%)	64	(7%)
35-44 years	100	(18%)	96	(15%)	124	(16%)	114	(14%)	114	(12%)
45-54 years	126	(22%)	145	(22%)	184	(24%)	188	(23%)	210	(23%)
55-64 years	137	(24%)	179	(27%)	192	(26%)	230	(28%)	257	(28%)
65-74 years	95	(17%)	95	(15%)	126	(17%)	160	(19%)	192	(21%)
75-84 years	26	(5%)	38	(6%)	36	(5%)	40	(5%)	61	(6%)
>=85 years	0	(0%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
Total	562	(100%)	655	(100%)	754	(100%)	827	(100%)	930	(100%)
Primary Renal Disease *										
Glomerulonephritis	74	(29%)	103	(29%)	97	(29%)	77	(23%)	87	(25%)
Analgesic Nephropathy	2	(<1%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
Hypertension	25	(11%)	52	(15%)	37	(11%)	32	(10%)	39	(11%)
Polycystic Disease	14	(5%)	11	(3%)	24	(7%)	12	(4%)	13	(4%)
Reflux Nephropathy	6	(2%)	19	(5%)	7	(2%)	11	(3%)	3	(1%)
Diabetic Nephropathy	103	(39%)	124	(35%)	123	(37%)	155	(46%)	146	(41%)
Miscellaneous	21	(8%)	30	(8%)	31	(9%)	38	(11%)	39	(11%)
Uncertain	14	(5%)	17	(5%)	17	(5%)	11	(3%)	25	(7%)
Total	259	(100%)	356	(100%)	336	(100%)	336	(100%)	352	(100%)
		* New patie								


Figure 5.6									
Proportion (%) of Patients aged >= 65 years Treated with Home Haemodialysis 1999 - 2003									
State	1999	2000	2001	2002	2003				
Queensland	1%	2%	1%	2%	2%				
New South Wales	7%	7%	6%	6%	7%				
Aust.Capital Territory	6%	7%	8%	7%	7%				
Victoria	3%	2%	3%	2%	2%				
Tasmania	0%	0%	0%	0%	0%				
South Australia	2%	<1%	2%	2%	<1%				
Northern Territory	0%	0%	0%	0%	0%				
Western Australia	<1%	<1%	<1%	<1%	<1%				
Australia	4%	3%	4%	4%	4%				
New Zealand	7%	5%	5%	5%	5%				

Figure 5.7

Age of New Haemodialysis Patients 2003 Australia Number (Total=1667) 17% 19% 24% 21%

5% 3% 1% 0.1% 15-24 25-34 35-44 45-54 55-64 65-74 75-84 >=85 No. Pats. 9 48 91 156 277 315 407 347 17

Figure 5.8



New Zealand (continued)

There were 352 patients who received haemodialysis for the first time, a 5% increase from 2002, 81% having their initial dialysis treatment. The modal age group was 45-74 years (70%), 10% were <35 years and 37% >=65 years (fig 5.5 and 5.9, and Appendix III at the Website (www.anzdata.org.au/ANZDATA/AnzdataReport/download.htm).

Sixty-four haemodialysis patients received transplants in 2003 (61 in 2002), representing 7% of all patients dialysing and 9% of those patients <65 years.

There were 132 deaths, at a rate of 15.0 deaths per 100 patient years of treatment, (10.5% of patients at risk) (fig 3.10).

Figure 5.9

Age of New Haemodialysis Patients 2003 New Zealand ■ Number (Total=352) 26% 25% 19% 11% 10% 5% 4% 0% 0% 25-34 35-44 45-54 55-64 65-74 75-84 >=85 15-24 No.

67

35

88

90

38

0


Figure 5.10

Pats.

0

20

14



BLOOD FLOW RATES

AUSTRALIA

The previous trend towards a prescribed blood flow rate of 300 mls/minute or higher has flattened: this group remained the same as last year at 76% of all patients. In March 1997 it was 47%. Only 6% were now prescribed less than 250 mls/minute.

Blood flow rates are lower in patients dialysing using central venous catheters than in those using fistulae or grafts (fig 5.12).

New ZEALAND

In March 2004, 71% of patients were prescribed 300 mls/minute or higher compared to 67% in 2003, 55% in 2002 and 21% in 1997. There were 8% still using <250 mls/minute, many of these receiving long session duration dialysis.


Figure 5.11									
Blood Flow Rates (mls/minute) 1997 - 2004									
C		No.			Mls/M	linute			
Country		Pts	<200	200-249	250-299	300-349	350-399	>400	
	March 2004	5924	<1%	6%	18%	55%	17%	4%	
	March 2003	5502	<1%	6%	18%	57%	16%	3%	
	March 2002	5128	<1%	6%	20%	56%	15%	3%	
	March 2001	4717	<1%	7%	23%	55%	11%	3%	
Aust	March 2000	4374	1%	8%	26%	54%	9%	2%	
	March 1999	4029	1%	10%	29%	51%	8%	1%	
	March 1998	3590	1%	10%	33%	49%	6%	1%	
	March 1997	3342	<1%	15%	37%	43%	4%	<1%	
	March 2004	938	<1%	8%	21%	45%	23%	3%	
	March 2003	826	<1%	10%	23%	43%	23%	1%	
	March 2002	761	<1%	15%	30%	37%	17%	1%	
NIT	March 2001	679	1%	13%	34%	36%	15%	1%	
NZ	March 2000	575	1%	19%	37%	35%	8%	<1%	
	March 1999	501	1%	25%	40%	26%	8%	0%	
	March 1998	441	1%	25%	44%	28%	2%	0%	
	March 1997	390	1%	30%	47%	21%	<1%	0%	

Figure 5	.12							
Blood Flow Rate and Type of Access March 2004								
		Australia		N	ew Zealan	d		
Blood Flow Rate	Native	Grafts	Catheters	Native	Grafts	Catheters		
<200	23 (<1%)	1 (<1%)	11 (2%)	2 (<1%)	-	3 (1%)		
200-249	181 (4%)	38 (4%)	115 (20%)	51 (8%)	1 (1%)	21 (9%)		
250-299	637 (14%)	187 (20%)	242 (41%)	100 (16%)	22 (24%)	76 (33%)		
300-349	2509 (57%)	576 (62%)	190 (32%)	247 (40%)	51 (54%)	121 (53%)		
350-399	861 (20%)	118 (13%)	26 (4%)	186 (30%)	20 (21%)	9 (4%)		
>=400	196 (4%)	12 (1%)	1 (<1%)	28 (5%)	-	-		
Total	4407 (100%)	932 (100%)	585 (100%)	614 (100%)	94 (100%)	230 (100%)		

Figure 5.13

Distribution of Blood Flow Rates Number of Patients (31 March) Australia 2002 (5128) 4000 -**2003** (5502) 3500 **2004** (5924) 3000 2500 2000 1500 1000 500 200-249 250-299 300-349 350-399 >=400 mls/min

Distribution of Blood Flow Rates





FREQUENCY AND HOURS OF DIALYSIS

Figure 5.14 **Duration and Number of Treatments Per Week** 31-Mar-2004 **Hours of Each Treatment** Total <2.5 2.5-2.9 3-3.4 3.5-3.9 4-4.4 4.5-4.9 5-5.4 5.5-5.9 6-6.4 > 6.5 week **Australia** 2.5 3.5 Total **New Zealand** 3.5 Total

Figure	Figure 5.15									
Dura	tion	of H	aemo	dialys	sis Pe	r Weel	c 31-	Mar-20	04	
Country	No.			Hours	of Haem	odialysis	odialysis Per Week			
Country	Pts	<9	9-11	12-14	15-17	18-20	21-23	24-26	>27	
Aust	5664	1%	7%	61%	27%	2%	<1%	<1%	<1%	
NZ	927	1%	3%	56%	33%	4%	<1%	2%	<1%	
	E		•			and haemo	diafiltration ekly	า		

AUSTRALIA

Figures 5.14-5.18.

Of the 5,924 patients, there were still 88 receiving dialysis twice a week (1.5%); the great majority (93%) dialysed three times per week.


Of the patients dialysing three times per week 30% were dialysing for five hours or longer, the same as in 2003; only 7% (7% 2003) received less than four hours. Forty five percent of patients dialysed for 4-4.4 hours.

The median weekly dialysis treatment period for all haemodialysis patients was 12 hours; range 3-50 hours.

The number of people dialysing five or more days per week continues to rise. The trends in more frequent dialysis are illustrated in Figure 5.16.

Sixty five percent of patients dialysing for longer than 5.5 hours and 66% of patients dialysing more than three times a week were dialysing at home.

Figure 5.16



New Zealand

Figures 5.14-5.18.

There were 896 patients (96%) dialysing three times per week. The proportion on frequent >=5 times a week dialysis is steady.

The majority (89%) dialysed between four and less than five and a half hours, three times a week. Only 26 patients (3%) dialysed for less than four hours.


The remainder dialysed for five and a half or more hours, three times a week.

Median weekly treatment for all haemodialysis patients was 13 hours, range 6-40 hours per week.

Seventy four percent of patients were dialysing at home for longer than 5.5 hours and more than three times a week.

Figure 5	5.17									
Number of Sessions Per Week (At 31-Mar) 1999 - 2004										
Sessions per week	1999	2000	2001	2002	2003	2004				
Austral	ia									
1	3	7	8	5	5	4				
2	78	80	83	76	73	88				
2.5	-	-	-	1	-	2				
3	3906	4213	4523	4827	5164	5519				
3.5	15	14	-	85	101	118				
4	20	50	82	84	83	91				
5	2	2	8	17	28	41				
6	5	8	12	29	45	59				
7	-	-	1	4	3	2				
Total	4029	4374	4717	5128	5502	5924				
New Ze	aland									
1	-	1	1	-	2	-				
2	10	11	12	16	13	11				
3	488	555	660	728	794	896				
3.5	-	-	-	2	4	10				
4	3	8	6	10	10	10				
5	-	-	-	2	-	4				
6	-	-	-	3	3	6				
7	-	-	-	-	-	1				
Total	501	575	679	761	826	938				

Figure 5.18



Duration of Dialysis Treatment Three Sessions Per Week






Figure 5.19

Haemodialyser Membrane Types by Surface Area Patients Alive on Haemodialysis at 31-Mar-2004

Dialyses Membrane Type	Flux		Sq	uare Met	res		Total
Dialyser Membrane Type	riux	<1.0	1.0-1.4	1.5-1.7	1.8-1.9	>1.9	lotai
Augtrolio							
Australia							
Cellulose Acetate	Low	0	3	7	0	3	13
Cellulose Triacetate	High	0	1	5	248	0	254
Cuprophan	Mid	0	0	0	3	15	18
Diacetate	Low	0	1	28	0	1	30
Exebrane	High	0	0	21	97	9	127
Exebrane	Mid	0	0	12	10	0	22
Haemophan	Low	0	19	136	11	322	488
Polyamide Haemodiafiltration	High	0	67	42	0	47	156
Polyamix	High	0	7	32	0	15	54
Polyamix	Low	0	216	756	0	0	972
Polysulphone	High	1	129	0	1107	244	1481
Polysulphone	Low	20	137	165	1031	579	1932
Polysulphone-Helixone	High	0	0	0	37	0	37
Polysynthane	Low	0	38	182	0	120	340
Total		21	618	1386	2544	1355	5924
New Zealand							
Cuprophan	Low	0	0	1	0	0	1
Haemophan	Low	0	3	24	0	252	279
Polyamide Hemodiafiltration	High	0	9	7	0	21	37
Polyamix	High	0	0	1	0	1	2
Polyamix	Low	0	20	103	0	0	123
Polycarbonate/Poly/Copolymer	Low	0	0	0	1	0	1
Polysulphone	High	0	6	0	48	0	54
Polysulphone	Low	0	20	1	396	24	441
Total		0	58	137	445	298	938

MEMBRANE TYPE AND SURFACE AREAS

AUSTRALIA

Figures 5.19-5.20.

Usage of low flux polysulfone dialysers decreased to 32% in March 2004 (36% in March 2003 and 42% in March 2002), while use of high flux polysulphone increased to 25% (18% in March 2003 and 13% in March 2002).

Thirty six percent of patients received dialysis with high flux dialysers (27% in March 2003, 24% in March 2002) and <1% of patients received mid flux dialysis. Use of haemophan continues to decrease from 22% in 2002 to 13% in March 2003 and 8% in March 2004.

The trend to larger surface area dialysers continues.

New ZEALAND

Figures 5.19-5.20.

Haemophan decreased from 37% in March 2003 to 30% in March 2004, while low flux polysulphone remained similar to last year (47% in 2004 and 46% in March 2003).


There were 10% (93 patients) reported as receiving high flux dialysis in 2004, an increase from 7% in March 2003.

Figure 5.20

Haemodialysis Surface Area

Number of Patients (31 March) Australia 2003 (5502) 2004 (5924) 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.4 Surface Area (sqm) 105 188 330 137 68 537 795 2021 189 421 150 16 545 137 39 301 1046 2296 248 331 185 340 111

Haemodialysis Surface Area



CALCIUM AND PHOSPHATE

The March 2004 survey was the first occasion when calcium and phosphate data were collected. Completion rates for this aspect were excellent, particularly for phosphate reporting.

The calcium and phosphate levels reported are tabled in Figures 5.21 and 5.22 and the calcium phosphate products are tabulated in Figure 5.23. They include all patients and dialysis modalities.

In coming surveys, this data will allow examination of associations between calcium/phosphate control and various outcomes.

	Ca	alcium	
Calcium	Mod	ality	TOTAL
(mmol/l)	HD	PD	IOIAL
Austral	lia		
<2.0	311 (5%)	111 (6%)	422 (5%)
2.0-2.1	891 (14%)	355 (18%)	1246 (15%)
2.2-2.3	2315 (35%)	686 (34%)	3001 (35%)
2.4-2.5	2045 (31%)	546 (27%)	2591 (30%)
>=2.6	809 (12%)	224 (11%)	1033 (12%)
Missing	176 (3%)	78 (4%)	254 (3%)
Total	6547 (100%)	2000 (100%)	8547 (100%)
New Ze	ealand		
<2.0	32 (3%)	41 (5%)	73 (4%)
2.0-2.1	95 (9%)	157 (18%)	252 (13%)
2.2-2.3	282 (27%)	265 (31%)	547 (29%)
2.4-2.5	443 (43%)	288 (34%)	731 (39%)
>=2.6	161 (16%)	90 (11%)	251 (13%)
Missing	20 (2%)	13 (2%)	33 (2%)
Total	1033 (100%)	854 (100%)	1887 (100%)

Figure 5.22									
Phosphate									
Phosphate	Mod	Modality							
(mmol/l)	HD	PD	TOTAL						
Australia	3								
<1.4	2311 (35%)	706 (35%)	3017 (35%)						
1.4-1.6	821 (13%)	280 (14%)	1101 (13%)						
1.6-1.7	1050 (16%)	310 (16%)	1360 (16%)						
>=1.8	2258 (34%)	636 (32%)	2894 (34%)						
Missing	107 (2%)	68 (3%)	175 (2%)						
Total	6547 (100%)	2000 (100%)	8547 (100%)						
New Zea	land								
<1.4	239 (2%)	274 (32%)	513 (27%)						
1.4-1.6	118 (11%)	87 (10%)	205 (11%)						
1.6-1.7	154 (15%)	144 (17%)	298 (16%)						
>=1.8	500 (48%)	336 (39%)	836 (44%)						
Missing	22 (2%)	13 (2%)	35 (2%)						
Total	1033 (100%)	854 (100%)	1887 (100%)						

Figure 5.23 Calcium / Phosphate									
Product	HD	PD	TOTAL						
Australi	ia								
<3.5	2633 (40%)	824 (41%)	3457 (40%)						
3.5-3.9	961 (15%)	349 (17%)	1310 (15%)						
4.0-4.4	813 (12%)	216 (11%)	1029 (12%)						
4.5-4.9	649 (10%)	206 (10%)	855 (10%)						
>=5.0	1308 (20%)	323 (16%)	1631 (19%)						
Missing	183 (3%)	82 (4%)	265 (3%)						
Total	6547 (100%)	2000 (100%)	8547 (100%)						
New Ze	aland								
<3.5	276 (27%)	312 (37%)	588 (31%)						
3.5-3.9	130 (13%)	127 (15%)	257 (14%)						
4.0-4.4	136 (13)	111 (13%)	247 (13%)						
4.5-4.9	114 (11%)	92 (11%)	206 (11%)						
>=5.0	357 (35%)	199 (23%)	556 (29%)						
Missing	20 (2%)	13 (2%)	33 (2%)						
Total	1033 (100%)	854 (100%)	1887 (100%)						

87 (38%)

39 (17%)

103 (44%)

4.0 - 4.4

4.5 - 4.9

>=5

Total

1599 (46%)

614 (18%)

979 (28%)

513 (43%)

207 (18%)

392 (33%)

3444 (100%) 1185 (100%)



Figure 5.24 **Duration of Treatments and Serum Phosphate Levels Haemodialysis - Three Sessions Per Week** March 2004 **Australia New Zealand** >2.2 >2.2 <1.8 1.8-2.2 <1.8 1.8-2.2 **Hours per** Session mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L <3.5 89 (3%) 36 (3%) 24 (2%) 10 (2%) 3 (1%) 1 (<1%) 3.5 - 3.9 163 (5%) 37 (3%) 33 (4%) 4 (1%) 8 (3%)

374 (43%)

173 (20%)

269 (31%)

873(100%)

171 (41%)

93 (22%)

140 (33%)

82 (34%)

48 (20%)

105 (43%)

418 (100%) 244 (100%) 232 (100%)

In Figure 5.25, the calcium, phosphate and CaP product is tabulated according to the standards suggested by the CARI guidelines (http://www.kidney.org.au/cari/drafts/cbiochem.html). For each parameter, the frequencies differ significantly between Australia and New Zealand (p<0.001).

Figure 5.2	5									
Percentage of Patients in Each CARI Guideline Category Dialysing Three Times a Week 1-Oct-2003 to 31-Mar-2004										
		Australia	New Zealand	TOTAL						
	0 - 2.1	1136 (19%)	122 (12%)	1258 (18%)						
Calcium	2.2 - 2.5	4051 (66%)	686 (70%)	4737 (67%)						
[mmol/l]	>=2.6	744 (12%)	153 (16%)	897 (13%)						
CARI	Missing	164 (3%)	18 (2%)	182 (2%)						
	Total	6095 (100%)	979 (100%)	7074 (100%)						
		Pearson chi2 (3) - 2	29.9022 Pr = 0.000							
	0 - 1.7	3885 (64%)	482 (49%)	4367 (62%)						
Phosphate	1.8 - 2.1	1104 (18%)	231 (24%)	1335 (19%)						
[mmol/l] (%)	>= 2.2	1021 (17%)	248 (25%)	1269 (18%)						
CARI	Missing	85 (1%)	18 (2%)	103 (1%)						
	Total	6095 (100%)	979 (100%)	7074 (100%)						
		Pearson chi2 (3) =	77.9512 Pr = 0.000							
	0 - 4.1	3681 (60%)	437 (45%)	4118 (58%)						
Calcium x	4.2 - 5.7	1638 (27%)	354 (36%)	1992 (28%)						
Phospate	>= 5.8	605 (10%)	170 (17%)	775 (11%)						
Product (%)	Missing	171 (3%)	18 (2%)	189 (3%)						
	Total	6095 (100%)	979 (100%)	7074 (100%)						
		Pearson chi2 $(3) = 1$	107.3506 Pr = 0.000							

UREA REDUCTION RATIO

The data return in this section is one of the poorest in the Registry. Overall, data has not been reported on 11% of Australian patients and 20% of New Zealand patients at 31st March 2004.

Figure 5.26 shows that 88% in Australia and 65% of patients in New Zealand receive a dialysis dose

commensurate with that recommended by the CARI guidelines (URR >=65%) at 31-Mar-04.

URR is lower in patients dialysing using catheters than in those using fistulae or grafts (fig 5.27).

Figure 5.26

Urea Reduction Ratio (URR) of Patients Alive on Haemodialysis At 30-Sep-2002 and 31-Mar-2004

Domested UDD		Aust	ralia		New Zealand				
Reported URR	30-Sep-02 31-Mar		30-Sep-03 31-Mar-04		30-Sep-02	31-Mar-03	30-Sep-03	31-Mar-04	
00-39%	<1%	<1%	<1%	<1%	<1%	<1%	1%	<1%	
40-49%	<1%	<1%	1%	1%	3%	3%	4%	2%	
50-59%	4%	4%	4%	4%	19%	15%	18%	15%	
60-64%	9%	9%	8%	8%	18%	22%	19%	18%	
65-69%	19%	19%	20%	18%	24%	22%	18%	23%	
70-74%	27%	27%	29%	29%	18%	18%	21%	20%	
75-79%	22%	23%	22%	23%	10%	11%	12%	12%	
80-100%	18%	17%	16%	17%	8%	8%	7%	10%	
Total Pts	4309	4512	4626	4924	589	597	666	714	
Median	73	73	72	73	67	68	67	68	
25th Percentile	68	68	68	68	61	61	60	62	
75th Percentile	78	77	77	77	73	73	73	74	

F	ig	ur	e.	5	.2	7
---	----	----	----	---	----	---

Urea Reduction Ratio and Type of Access Haemodialysis - Three Sessions Per Week March 2004

		Aust	ralia		New Zealand					
URR	Native	Grafts	Catheters	Total	Native	Grafts	Catheters	Total		
<60	152 (4%)	16 (1%)	61 (11%)	229 (4%)	71 (12%)	7 (7%)	46 (20%)	124 (14%)		
60-64	283 (7%)	40 (4%)	61 (11%)	384 (7%)	87 (15%)	11 (12%)	32 (14%)	130 (15%)		
65-69	709 (17%)	104 (12%)	83 (15%)	896 (16%)	98 (17%)	23 (26%)	43 (19%)	164 (18%)		
70-74	1142 (28%)	193 (22%)	98 (18%)	1433 (26%)	101 (17%)	13 (15%)	28 (12%)	142 (16%)		
>=75	1415 (35%)	431 (49%)	136 (25%)	1982 (36%)	94 (16%)	21 (23%)	39 (17%)	154 (17%)		
Unknown	376 (9%)	104 (12%)	115 (21%)	595 (11%)	130 (22%)	14 (16%)	38 (17%)	182 (20%)		
Total	4077 (100%)	888 (100%)	544 (100%)	5519 (100%)	581 (100%)	89 (100%)	226 (100%)	896 (100%)		



Access at First Treatment

Data collection for access used at first haemodialysis commenced from 1st October 2003.

As well as patients having their first treatment on haemodialysis, data collected also includes patients previously having peritoneal dialysis and changing to haemodialysis, and patients returning to dialysis after graft failure where haemodialysis was given for the first time. Here, we have only presented data for those whose first treatment was haemodialysis.

The use of catheters is similar between Australia and New Zealand for incident patients (fig 5.28), although lower in Australia for prevalent dialysis.

Access type for both incident and prevalent dialysis patients is variable among Australian States (fig 5.29).

Figure 5.28									
First Access Haemodialysis as Initial Modality 1-Oct-03 to 31-Mar-2004									
First Access	Соц	TOTAL							
THISE ACCESS	Australia	New Zealand	IOTAL						
Native	256 (39%)	42 (35%)	298 (38%)						
Synthetic	18 (3%)	2 (2%)	20 (3%)						
Tunnel CV	247 (37%)	31 (26%)	278 (36%)						
Non Tunnel CV	140 (21%)	44 (38%)	184 (24%)						
Total	661 (100%)	119 (100%)	780 (100%)						

gure 5.29 Australian Stat											
First Access Haemodialysis as Initial Modality 1-Oct-03 to 31-Mar-2004											
First Access	QLD	NSW	ACT	VIC	TAS	SA	NT	WA	TOTAL		
Native	47 (38%)	56 (28%)	1 (10%)	85 (49%)	-	35 (56%)	12 (48%)	20 (3%)	256 (39%		
Synthetic	7 (6%)	8 (4%)	1 (10%)	1 (<1%)	-	1 (2%)	-	-	18 (3%)		
Tunnel CV	49 (40%)	70 (35%)	8 (80%)	64 (37%)	3 (75%)	14 (23%)	11 (44%)	28 (45%)	247 (37%		
Non Tunnel CV	21 (17%)	66 (33%)	-	24 (13%)	1 (25%)	12 (20%)	2 (8%)	14 (23%)	140 (21%		
Total	124 (100%)	200 (100%)	10 (100%)	174 (100%)	4 (100%)	62 (100%)	25 (100%)	62 (100%)	661 (100%		

A graph of this Table is also available to download from the PowerPoint slides at www.anzdata.org.au

Access in use at first dialysis did not vary with age among diabetics in Australia or New Zealand.

In Australia (but not New Zealand), there was significant variation with higher rates of native fistulae seen among those aged 25-75 years at dialysis start (p=0.04).

Figure 5.30									
Age at First Treatment Access in use where first Treatment was Haemodialysis 1-Oct-2003 to 31-Mar-2004									
Deleted to Discoso			Age G	roups			Total		
Related to Disease	00-24	25-54	55-64	65-74	75-84	>=85	Total		
Australia									
Diabetic Patients									
Native	-	25	21	17	5	-	68		
Synthetic	-	1	3	2	-	-	6		
Tunnel CV Catheter	-	27	15	17	6	-	65		
Non Tunnel CV Catheter	-	11	12	11	3	-	37		
Sub TOTAL	-	64	51	47	14	-	176		
Non Diabetic Patients									
Native	3	64	35	47	36	3	188		
Synthetic	-	7	2	1	2	-	12		
Tunnel CV Catheter	9	46	34	36	50	7	182		
Non Tunnel CV Catheter	7	25	13	34	22	2	103		
Sub TOTAL	19	142	84	118	110	12	485		
TOTAL	19	206	135	165	124	12	661		
		(p=	0.04)						
New Zealand									
Diabetic Patients									
Native	-	5	6	2	1	-	14		
Synthetic	-	-	-	1	-	-	1		
Tunnel CV Catheter	-	6	1	3	1	-	11		
Non Tunnel CV Catheter	-	5	5	6	-	-	16		
Sub TOTAL	-	16	12	12	2	-	42		
Non Diabetic Patients									
Native	1	12	10	3	2	-	28		
Synthetic	-	-	-	-	1	-	1		
Tunnel CV Catheter	-	9	3	5	3	-	20		
Non Tunnel CV Catheter	2	9	5	6	6	-	28		
Sub TOTAL	3	30	18	14	12	-	77		
TOTAL	3	46	30	26	14	_	119		



Access in Use at 31st March 2004

Figure 5.31

Percentage Synthetic Fistulae/Grafts March 2004

Number of Patients (% Patients)

			,
	No. of Pts.	Diabetic	Non Diabetic
Queensland	1002	232 (14%)	770 (13%)
New South Wales	1839	292 (26%)	1547 (24%)
Aust. Capital Territory	130	19 (37%)	111 (46%)
Victoria	1615	324 (10%)	1291 (10%)
Tasmania	118	25 (8%)	93 (5%)
South Australia	409	79 (11%)	330 (12%)
Northern Territory	215	105 (3%)	110 (2%)
Western Australia	596	168 (7%)	428 (13%)
Australia	5924	1244 (14%)	4680 (16%)
March 2003	(5502)	1092 (15%)	4410 (17%)
New Zealand	938	356 (10%)	582 (10%)
March 2003	(826)	277 (14%)	549 (13%)

Figures 5.31 to 5.34 describe the data about prevalent haemodialysis access (i.e. access in use at 31st March 2004). These patterns are similar to previous: overall native fistulas predominate. The proportion with central catheters are substantially higher in New Zealand.

Figure 5.33

Type of Access for Haemodialysis Australia March 2004




Figure 5.32

Percentage of Non Native Access March 2004

n = Number of Patients

		tralia :5924)	New Zealar (n=938)			
	Grafts	Catheters	Grafts	Catheters		
Total HD Population Diabetics Female	16% 14% 22%	10% 12% 12%	10% 10% 15%	25% 30% 30%		

Type of Access for Haemodialysis New Zealand March 2004




Figure 5.34

Access Intervention in Previous Six Months March 2004

n = Number of Patients										
		Rev	vision of <i>l</i>	Access	Dec	lotting of	Access			
		Native Grafts Catheters		Native	Grafts	Catheters				
Australia	n=5924	8%	25%	18%	4%	20%	21%			
Diabetics	n=1244	10%	318%	18%	5%	20%	18%			
Female	n=2377	10%	235%	21%	4%	18%	21%			
New Zealand	n=938	10%	30%	7 %	4%	16%	10%			


PATIENT BODY MASS INDEX


There has been considerable interest in BMI in recent years and the Registry has received several requests for information.

There has been a gradual increase in the BMI of those commencing dialysis, shown in Figure 5.36.

The graph in Figure 5.35 illustrates similar information in a box plot, showing 25th, 50th and 75th centiles together with the "adjacent values" (which approximate 95th centiles).

Figure 5.35





Year of First Treatment



Figur	e 5.36										
	Patien	t Bod	y Mass	Inde	x at Fi	rst Tr	eatmen	it	1999 -	2003	
Voor	DMT					Age	Groups				
Year	ВМІ	20	-34	3!	5-54	55	5-74	>	=75	Т	otal
Austr	ralia										
Austi	1	25	(210/)	26	(100/)	62	(10%)	25	(1 = 0/)	140	(120/.)
	<20 20-24.9		(21%) (51%)		(10%) (34%)		(36%)		(15%) (43%)		(12%) (38%)
1999	25-29.9		(20%)		(33%)		(31%)		(32%)		(31%)
1999	>=30		(7%)		(23%)		(22%)		(9%)		(19%)
	Total	120	(100%)		(100%)		(100%)		(100%)		(100%)
	<20	11	(9%)	43	(12%)	62	(11%)	26	(12%)	142	(11%)
	20-24.9	68	(57%)	113	(32%)	191	(33%)	91	(43%)	463	(37%)
2000	25-29.9	29	(24%)	100	(29%)	207	(35%)	66	(31%)	402	(32%)
	>=30	11	(9%)	91	(26%)	125	(21%)	26	(12%)	253	(20%)
	Total	199	(100%)	347	(100%)	585	(100%)	209	(100%)	1260	(100%)
	<20	15	(13%)	36	(9%)	55	(9%)	32	(14%)	138	(10%)
	20-24.9	47	(42%)	132	(34%)	213	(34%)	93	(40%)	485	(36%)
2001	25-29.9	28	(25%)	119	(31%)	196	(31%)	70	(30%)	413	(30%)
	>=30	22	(20%)	97	(25%)		(26%)	36	(16%)	319	(24%)
	Total		(100%)		(100%)	628	(100%)	231	(100%)	1355	(100%)
	<20		(13%)		(10%)		(6%)		(15%)		(9%)
	20-24.9		(46%)		(29%)		(28%)		(37%)		(31%)
2002	25-29.9		(22%)		(35%)		(38%)		(36%)		(35%)
	>=30		(18%)		(26%)		(29%)		(12%)		(24%)
	Total		(100%)		(100%)		(100%)		(100%)		(100%)
	<20		(17%)		(10%)		(8%)		(9%)		(10%)
	20-24.9		(38%)		(31%)		(31%)		(44%)		(35%)
2003	25-29.9		(24%		(31%)		(35%)		(35%)		(33%)
	>=30		(19%)		(27%)		(26%)		(12%)		(23%)
	Total	98	(100%)	3//	(100%)	014	(100%)	301	(100%)	1390	(100%)
New 2	Zealand										
	<20	7	(32%)	3	(5%)	5	(6%)	3	(15%)	18	(10%)
	20-24.9	6	(27%)	14	(23%)	20	(24%)	8	(40%)	48	(26%)
1999	25-29.9	6	(27%)	24	(39%)	24	(29%)	5	(25%)	59	(32%)
	>=30	3	(14%)	19	(31%)	32	(39%)	3	(15%)	57	(31%)
	Total	22	(100%)	60	(100%)	81	(100%)	19	(100%)	182	(100%)
	<20	2	(6%)	5	(6%)	10	(8%)	3	(18%)	20	(8%)
	20-24.9		(60%)		(29%)		(27%)	4	(24%)	84	(32%)
2000	25-29.9		(14%)		(27%)		(30%)		(59%)		(29%)
	>=30		(20%)		(37%)		(33%)		(0%)		(30%)
	Total	35	(100%)		(100%)	123	(100%)		(100%)	260	(100%)
	<20		(10%)		(5%)		(4%)		(16%)		(6%)
	20-24.9		(45%)		(16%)		(35)		(53%)		(30%)
2001	25-29.9		(15%)		(28%)		(22%)		(16%)		(24%)
	>=30		(30%)		(49%)		(38%)		(16%)		(40%)
	Total		(100%)		(100%)		(100%)		(100%)		(100%)
	<20		(19%)		(4%)		(7%)		(13%)		(6%)
	20-24.9		(41%)		(24%)		(23%)		(60%)		(26%)
2002	25-29.9 >=30		(18%)		(28%)		(29%) (42%)		(7%) (20%)		(27%)
			(29%)		(43%)		(42%)		(20%)		(40%)
	Total		(100%)		(100%)		(100%)		(100%)		(100%)
	<20		(9%)		(2%)		(4%)		(14%)		(5%)
	20-24.9		(32%)		(21%)		(20%)		(24%)		(22%)
2003	25-29.9 >=30		(32%)		(42%) (35%		(31%)		(28%)		(34%)
			(27%)		(35%		(45%)		(35%)		(39%)
	Total	22	(100%)	83	(100%)	145	(100%)	29	(100%)	279	(100%)